Sugi Predict

Sugi Predict / Compounds / SCHEMBL2988932

SCHEMBL2988932

SCHEMBL2988932

CC1(C)C(=O)NC(=O)N1CCNc1nccc(-c2cc3cc(NC(=O)Cc4ccccc4)ccc3s2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IKBKB O14920 8/20 0.46
▸ HDAC1 Q13547 2/20 0.45
▸ CHUK O15111 5/20 0.41
▸ IKBKG Q9Y6K9 5/20 0.41
▸ ROCK2 O75116 2/20 0.38
▸ RAF1 P04049 2/20 0.38
▸ BRAF P15056 2/20 0.38
▸ PIK3CA P42336 1/20 0.37
▸ IGF1R P08069 2/20 0.37
▸ EGFR P00533 1/20 0.37
▸ ERBB2 P04626 1/20 0.37
▸ ROCK1 Q13464 1/20 0.37
▸ CSF1R P07333 1/20 0.37
▸ RET P07949 1/20 0.37
▸ FLT1 P17948 1/20 0.37
▸ KDR P35968 1/20 0.37
▸ MAP4K2 Q12851 1/20 0.37
▸ STK3 Q13188 1/20 0.37
▸ MAP4K5 Q9Y4K4 1/20 0.37
▸ SYK P43405 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3177282 0.94 IKBKB (0.41) IKBKBHDAC1CHUKIKBKGRAF1
SCHEMBL2983021 0.93 PSMB8 (0.41) IKBKBHDAC1CHUKIKBKGRAF1
SCHEMBL2984268 0.89 PDGFRB (0.46) IKBKBHDAC1CHUKIKBKGEGFR
SCHEMBL2983663 0.88 IKBKB (0.39) IKBKBCHUKIKBKGPIK3CASYK
SCHEMBL2975834 0.88 SENP7 (0.38) IKBKBCHUKIKBKGSYK
SCHEMBL2987595 0.87 IKBKB (0.41) IKBKBCHUKIKBKGKDRSYK
SCHEMBL2976742 0.87 IKBKB (0.38) IKBKBCHUKIKBKGKDRSYK
SCHEMBL2975941 0.86 IKBKB (0.38) IKBKBCHUKIKBKGRAF1BRAF
SCHEMBL2983796 0.86 IKBKB (0.38) IKBKBCHUKIKBKGSYK
SCHEMBL2974915 0.86 IKBKB (0.35) IKBKBCHUKIKBKGSYKLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1831207-B1 AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS AMGEN INC (US) 2012-11-14 — — EP disclosed
US-7858785-B2 Aminopyrimidine compounds and methods of use AMGEN INC. (US) 2010-12-28 — — US disclosed
US-7786132-B2 Aminopyrimidine compounds and methods of use AMGEN INC. (US) 2010-08-31 — — US disclosed
US-20100010014-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2010-01-14 — — US disclosed
EP-1831207-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2007-09-12 — — EP disclosed
US-20070185133-A1 Aminopyrimidine compounds and methods of use AMGEN, INC. (US) 2007-08-09 — — US disclosed
WO-2006066172-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE AMGEN, INC. (US) 2006-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010014-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE PLK1, TYMP, TK2 IKBKB 1952/4885HDAC1 2422/4885CHUK 1311/4885
US-20070185133-A1 Aminopyrimidine compounds and methods of use PLK1, TYMP, TK2 IKBKB 1952/4885HDAC1 2422/4885CHUK 1311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.